Armata Pharmaceuticals Stock Fundamentals
| ARMP Stock | USD 1.95 0.02 1.02% |
Armata Pharmaceuticals fundamentals help investors to digest information that contributes to Armata Pharmaceuticals' financial success or failures. It also enables traders to predict the movement of Armata Stock. The fundamental analysis module provides a way to measure Armata Pharmaceuticals' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Armata Pharmaceuticals stock.
Armata |
Armata Pharmaceuticals Company Shares Outstanding Analysis
Armata Pharmaceuticals' Outstanding Shares are shares of common stock of a public company that were purchased by investors after they were authorized and issued by the company to the public. Outstanding Shares are typically reported on fully diluted basis, including exotic instruments such as options, or convertibles bonds.
Current Armata Pharmaceuticals Shares Outstanding | 36.18 M |
Most of Armata Pharmaceuticals' fundamental indicators, such as Shares Outstanding, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Armata Pharmaceuticals is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Outstanding shares that are stated on company Balance Sheet are used when calculating many important valuation and performance indicators including Return on Equity, Market Cap, EPS and many others.
| Competition |
Based on the latest financial disclosure, Armata Pharmaceuticals has 36.18 M of shares currently outstending. This is 79.96% lower than that of the Biotechnology sector and 66.14% lower than that of the Health Care industry. The shares outstanding for all United States stocks is 93.67% higher than that of the company.
Armata Pharmaceuticals Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Armata Pharmaceuticals's current stock value. Our valuation model uses many indicators to compare Armata Pharmaceuticals value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Armata Pharmaceuticals competition to find correlations between indicators driving Armata Pharmaceuticals's intrinsic value. More Info.Armata Pharmaceuticals is rated fifth in return on equity category among its peers. It is rated second in return on asset category among its peers . Comparative valuation analysis is a catch-all technique that is used if you cannot value Armata Pharmaceuticals by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.Armata Shares Outstanding Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Armata Pharmaceuticals' direct or indirect competition against its Shares Outstanding to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Armata Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Armata Pharmaceuticals by comparing valuation metrics of similar companies.Armata Pharmaceuticals is currently under evaluation in shares outstanding category among its peers.
Armata Fundamentals
| Return On Equity | -34.39 | ||||
| Return On Asset | -0.25 | ||||
| Operating Margin | (3.28) % | ||||
| Current Valuation | 191.57 M | ||||
| Shares Outstanding | 36.18 M | ||||
| Shares Owned By Insiders | 70.24 % | ||||
| Shares Owned By Institutions | 3.84 % | ||||
| Number Of Shares Shorted | 6.04 K | ||||
| Price To Earning | (1.65) X | ||||
| Price To Book | 4.06 X | ||||
| Price To Sales | 13.04 X | ||||
| Revenue | 4.53 M | ||||
| Gross Profit | (28.05 M) | ||||
| EBITDA | (39.92 M) | ||||
| Net Income | (69.05 M) | ||||
| Cash And Equivalents | 36.98 M | ||||
| Cash Per Share | 1.02 X | ||||
| Total Debt | 120.37 M | ||||
| Debt To Equity | 0.73 % | ||||
| Current Ratio | 5.59 X | ||||
| Book Value Per Share | (1.41) X | ||||
| Cash Flow From Operations | (47.42 M) | ||||
| Short Ratio | 0.66 X | ||||
| Earnings Per Share | (1.15) X | ||||
| Target Price | 7.0 | ||||
| Number Of Employees | 66 | ||||
| Beta | 0.9 | ||||
| Market Capitalization | 71.28 M | ||||
| Total Asset | 98.36 M | ||||
| Retained Earnings | (308.82 M) | ||||
| Working Capital | 2.69 M | ||||
| Current Asset | 4.48 M | ||||
| Current Liabilities | 4.08 M | ||||
| Net Asset | 98.36 M |
About Armata Pharmaceuticals Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Armata Pharmaceuticals's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Armata Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Armata Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.Armata Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on the development of targeted bacteriophage therapeutics for antibiotic-resistant infections worldwide. It has a partnership agreement with Merck Co. for developing synthetic bacteriophage candidates to target undisclosed infectious disease agents. Armata Pharmaceuticals operates under Biotechnology classification in the United States and is traded on AMEX Exchange. It employs 69 people.
Additional Tools for Armata Stock Analysis
When running Armata Pharmaceuticals' price analysis, check to measure Armata Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Armata Pharmaceuticals is operating at the current time. Most of Armata Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Armata Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Armata Pharmaceuticals' price. Additionally, you may evaluate how the addition of Armata Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.